The risk of cancer attributable to diagnostic medical radiation: Estimation for France in 2015.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 06 2019
Historique:
received: 23 02 2018
revised: 26 11 2018
accepted: 27 11 2018
pubmed: 12 12 2018
medline: 9 10 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

Although medical ionizing radiation (IR) has clear clinical benefits, it is an established carcinogen. Our study estimates the number of new cancer cases in France in 2015 attributable to IR exposure from medical procedures. Exposures from external (X-rays, CT scans, interventional radiology) and internal (nuclear medicine) sources were considered. We used 2007 national frequencies of diagnostic examinations by sex and age to estimate the lifetime organ dose exposure adjusted for changes in the use of such procedures over time. The Biological Effects of Ionizing Radiation VII risk models were used to estimate the corresponding excess cancer risk, assuming an average latency period of 10 years. Additionally, we used cancer incidence data from the French Cancer Registries Network. Of the 346,000 estimated new cancer cases in adults in France in 2015, 2300 cases (940 among men and 1360 among women) were attributable to diagnostic IR, representing 0.7% of all new cancer cases (0.5% for men and 0.9% for women). The leading cancers attributable to medical IR were female breast (n = 560 cases), lung (n = 500 cases) and colon (n = 290 cases) cancers. Compared to other risk factors, the contribution of medical IR to the cancer burden is small, and the benefits largely outweigh its harms. However, some of these IR-associated cancer cases may be preventable through dose optimization of and enhanced justification for diagnostic examinations.

Identifiants

pubmed: 30537057
doi: 10.1002/ijc.32048
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2954-2963

Informations de copyright

© 2019 UICC.

Auteurs

Claire Marant-Micallef (C)

Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.

Kevin D Shield (KD)

Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.

Jérôme Vignat (J)

Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.

Enora Cléro (E)

Institute for Radiological Protection and Nuclear Safety, Fontenay-aux-Roses, France.

Ausrele Kesminiene (A)

Senior Visiting Scientist, Section of Environment and Radiation, International Agency for Research on Cancer, Lyon, France.

Catherine Hill (C)

Institut Gustave Roussy, Villejuif, France.

Agnès Rogel (A)

Santé Publique France, Saint-Maurice, France.

Blandine Vacquier (B)

Santé Publique France, Saint-Maurice, France.

Freddie Bray (F)

Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.

Dominique Laurier (D)

Institute for Radiological Protection and Nuclear Safety, Fontenay-aux-Roses, France.

Isabelle Soerjomataram (I)

Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH